The impact of dendritic cell-tumor fusion cells on cancer vaccines - past progress and future strategies.
Dendritic cells (DCs) are potent antigen-presenting cells that can be used in cancer vaccines. Thus, various strategies have been developed to deliver tumor-associated antigens via DCs. One strategy includes administering DC-tumor fusion cells (DC-tumor FCs) to induce antitumor immune responses in cancer patients. However, clinical trials using this strategy have fallen short of expectations. Several factors might limit the efficacy of these anticancer vaccines. To induce efficient antitumor immune responses and enhance potential clinical benefits, DC-tumor FC-based cancer vaccines require manipulations that improve immunogenicity for both DCs and whole tumor cells. This review addresses recent progress in improving clinical outcomes using DC-tumor FC-based cancer vaccines.
Division of Gastroenterology & Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Mikio
M
Kajihara
Division of Gastroenterology & Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Kazuki
K
Takakura
Division of Gastroenterology & Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Toshifumi
T
Ohkusa
Division of Gastroenterology & Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Shigeo
S
Koido
D017951:Antigen Presentation; D000951:Antigens, Neoplasm / Q000276:immunology / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D002459:Cell Fusion / Q000639:trends; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines
cancer vaccines; dendritic cell; dendritic cell–tumor fusion cell; immunogenicity; whole tumor cell